- Home
- PPC vs BBIO Comparison
PPC vs BBIO Comparison
Compare PPC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPC
- BBIO
- Stock Information
- Founded
- PPC 1946
- BBIO 2015
- Country
- PPC United States
- BBIO United States
- Employees
- PPC N/A
- BBIO N/A
- Industry
- PPC Meat/Poultry/Fish
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PPC Consumer Staples
- BBIO Health Care
- Exchange
- PPC Nasdaq
- BBIO Nasdaq
- Market Cap
- PPC 9.0B
- BBIO 10.4B
- IPO Year
- PPC 1987
- BBIO 2019
- Fundamental
- Price
- PPC $38.01
- BBIO $65.97
- Analyst Decision
- PPC Hold
- BBIO Strong Buy
- Analyst Count
- PPC 3
- BBIO 19
- Target Price
- PPC $47.67
- BBIO $74.79
- AVG Volume (30 Days)
- PPC 1.8M
- BBIO 2.7M
- Earning Date
- PPC 10-29-2025
- BBIO 10-29-2025
- Dividend Yield
- PPC 22.13%
- BBIO N/A
- EPS Growth
- PPC 24.34
- BBIO N/A
- EPS
- PPC 5.16
- BBIO N/A
- Revenue
- PPC $18,351,780,000.00
- BBIO $353,780,000.00
- Revenue This Year
- PPC $3.98
- BBIO $123.32
- Revenue Next Year
- PPC $0.51
- BBIO $73.46
- P/E Ratio
- PPC $7.35
- BBIO N/A
- Revenue Growth
- PPC 1.76
- BBIO 62.46
- 52 Week Low
- PPC $35.73
- BBIO $21.72
- 52 Week High
- PPC $57.16
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- PPC 47.00
- BBIO 67.23
- Support Level
- PPC $36.03
- BBIO $60.55
- Resistance Level
- PPC $38.26
- BBIO $64.44
- Average True Range (ATR)
- PPC 1.06
- BBIO 3.32
- MACD
- PPC 0.20
- BBIO 0.23
- Stochastic Oscillator
- PPC 75.47
- BBIO 77.24
About PPC Pilgrim's Pride Corporation
Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed that JBS' offer undervalued Pilgrim's Pride.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.